Zai Lab Limited
ZLAB
NASDAQ·Healthcare·Biotechnology·Mkt cap $3.0B
$26.23
▼ -2.85%
P/E
-26.23
Mkt Cap
$3.0B
52-Wk Range
$15.96–$34.72
52-Week Range
$15.96 - $34.72
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 14.7% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
No bull reasons captured for this rating yet.
Bear Case
1 risk
- Low volatility (beta 0.8).
Growth
Strong growth ahead
Value
Deep value opportunity - significant discount to sector peers
Momentum
Hot
+57.8% over 3m
Quality
Strong
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying ZLAB right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 5, 2026
AUG 6, 2026
Reported EPS of -$0.46 vs -$0.68 consensus (+32.3% surprise). Revenue of $106.3M vs $103.9M expected (+2.4%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+32.3%
Revenue trend · last 2Q
—
-3%
Q1 26
Q2 26
$99.6M
$106.3M
Margins · last 2Q
Gross
54.7%
Operating
-72.0%
Profit
-47.8%
Wall Street consensus
2 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Citi · Aug 7, 2026
vs Industry
How ZLAB stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.